Answers are grounded in this paper and cite their sources.
Uncontrolled studies support a benefit of intravitreal bevacizumab in neovascular AMD for 3 months to 1 year. Low cost is a significant advantage of bevacizumab. Patients should discuss the potential risks and benefits of intravitreal bevacizumab and other available therapies with their physicians before receiving treatment. Controlled trials are needed to characterize the safety and efficacy of intravitreal bevacizumab and determine the optimal treatment regimen.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: